5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The tamoxifen derivative ridaifen-B is a high affinity selective CB 2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects

      , , , ,
      Toxicology and Applied Pharmacology
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="P1">Selective estrogen receptor modulators (SERMs) target estrogen receptors (ERs) to treat breast cancer and osteoporosis. Several SERMs exhibit anti-cancer activity not related to ERs. To discover novel anti-cancer drugs acting via ER-independent mechanisms, derivatives of the SERM tamoxifen, known as the “ridaifen” compounds, have been developed that exhibit reduced or no ER affinity, while maintaining cytotoxicity. Tamoxifen and other SERMs bind to cannabinoid receptors with moderate affinity. Therefore, ER-independent effects of SERMs might be mediated via cannabinoid receptors. This study determined whether RID-B, a first generation ridaifen compound, exhibits affinity and/or activity at CB <sub>1</sub> and/or CB <sub>2</sub> cannabinoid receptors. RID-B binds with high affinity (K <sub>i</sub> = 43.7 nM) and 17-fold selectivity to CB <sub>2</sub> over CB <sub>1</sub> receptors. RID-B acts as an inverse agonist at CB <sub>2</sub> receptors, modulating G-protein and adenylyl cyclase activity with potency values predicted by CB <sub>2</sub> affinity. Characteristic of an antagonist, RID-B co-incubation produces a parallel-rightward shift in the concentration-effect curve of CB <sub>2</sub> agonist WIN-55,212-2 to inhibit adenylyl cyclase activity. CB <sub>2</sub> inverse agonists are reported to exhibit anti-inflammatory and anti-ostoeclastogenic effects. In LPS-activated macrophages, RID-B exhibits anti-inflammatory effects by reducing levels of nitric oxide (NO), IL-6 and IL-1α, but not TNFα. Only reduction of NO concentration by RID-B is mediated by cannabinoid receptors. RID-B also exhibits pronounced anti-osteoclastogenic effects, reducing the number of osteoclasts differentiating from primary bone marrow macrophages in a cannabinoid receptor-dependent manner. In summary, the tamoxifen derivative RID-B, developed with reduced affinity for ERs, is a high affinity selective CB <sub>2</sub> inverse agonist with anti-inflammatory and anti-osteoclastogenic properties. </p>

          Related collections

          Author and article information

          Journal
          Toxicology and Applied Pharmacology
          Toxicology and Applied Pharmacology
          Elsevier BV
          0041008X
          August 2018
          August 2018
          : 353
          : 31-42
          Article
          10.1016/j.taap.2018.06.009
          6487498
          29906493
          4416610b-00db-4dbb-a330-e52cbd12b134
          © 2018

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article